Real-World Assessment of All-Cause Hospital Readmissions among Pulmonary Embolism Patients Treated W...
Real-World Assessment of All-Cause Hospital Readmissions among Pulmonary Embolism Patients Treated With Rivaroxaban Versus Apixaban
About this item
Full title
Author / Creator
Publisher
United States: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
United States: SAGE Publications
Subjects
More information
Scope and Contents
Contents
BackgroundAlthough hospital readmission after pulmonary embolism (PE) is common, there is limited evidence on the comparative risk of readmission between rivaroxaban and apixaban. This study compared the real-world risk of all-cause hospital readmission among patients with PE treated with rivaroxaban or apixaban.MethodsThis retrospective study used...
Alternative Titles
Full title
Real-World Assessment of All-Cause Hospital Readmissions among Pulmonary Embolism Patients Treated With Rivaroxaban Versus Apixaban
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c865025a686047c8a6b9b9eac82d475a
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c865025a686047c8a6b9b9eac82d475a
Other Identifiers
ISSN
1076-0296,1938-2723
E-ISSN
1938-2723
DOI
10.1177/10760296251327592
